{"id":10,"date":"2026-07-23T03:59:17","date_gmt":"2026-07-23T03:59:17","guid":{"rendered":"https:\/\/cu-genome.org\/?page_id=10"},"modified":"2026-07-23T04:03:09","modified_gmt":"2026-07-23T04:03:09","slug":"compound-universe-genome","status":"publish","type":"page","link":"https:\/\/cu-genome.org\/","title":{"rendered":"Compound Universe Genome"},"content":{"rendered":"<style>\n.cug-home {\n  --ink: #132c2b;\n  --ink-soft: #3f5d59;\n  --green: #087464;\n  --green-dark: #07584e;\n  --mint: #dff2eb;\n  --mint-soft: #f1f8f5;\n  --cream: #f6f3e9;\n  --line: #d6e2dd;\n  --white: #ffffff;\n  color: var(--ink);\n  background: var(--white);\n  font-family: inherit;\n  font-size: 18px;\n  line-height: 1.65;\n  overflow: hidden;\n}\n.cug-home *,\n.cug-home *::before,\n.cug-home *::after { box-sizing: border-box; }\n.cug-home h1,\n.cug-home h2,\n.cug-home h3 {\n  color: var(--ink);\n  line-height: 1.08;\n  letter-spacing: -.035em;\n  text-wrap: balance;\n}\n.cug-home h1 {\n  max-width: 940px;\n  margin: 0;\n  font-size: clamp(3.3rem, 8vw, 7rem);\n  font-weight: 760;\n  letter-spacing: -.06em;\n  line-height: .96;\n}\n.cug-home h2 {\n  max-width: 850px;\n  margin: 0 0 20px;\n  font-size: clamp(2.2rem, 4.5vw, 4rem);\n}\n.cug-home h3 {\n  margin: 0 0 10px;\n  font-size: 1.25rem;\n  letter-spacing: -.02em;\n}\n.cug-home p { color: var(--ink-soft); }\n.cug-shell {\n  width: min(1180px, calc(100% - 40px));\n  margin-inline: auto;\n}\n.cug-section { padding: clamp(72px, 9vw, 125px) 0; }\n.cug-eyebrow {\n  margin: 0 0 16px !important;\n  color: var(--green) !important;\n  font-size: 12px;\n  font-weight: 800;\n  letter-spacing: .13em;\n  text-transform: uppercase;\n}\n.cug-intro {\n  max-width: 760px;\n  margin: 0 0 40px;\n  font-size: 1.08rem;\n}\n.cug-hero {\n  position: relative;\n  padding: clamp(84px, 12vw, 165px) 0 clamp(78px, 10vw, 135px);\n  background:\n    radial-gradient(circle at 84% 23%, rgba(8,116,100,.16), transparent 24%),\n    radial-gradient(circle at 66% 90%, rgba(255,255,255,.95), transparent 28%),\n    linear-gradient(135deg, var(--cream) 0%, #eef8f4 58%, #d9f0e8 100%);\n  border-bottom: 1px solid var(--line);\n}\n.cug-hero::after {\n  content: \"\";\n  position: absolute;\n  width: 420px;\n  height: 420px;\n  top: -150px;\n  right: -100px;\n  border: 1px solid rgba(8,116,100,.15);\n  border-radius: 50%;\n  box-shadow:\n    0 0 0 70px rgba(255,255,255,.12),\n    0 0 0 140px rgba(8,116,100,.035);\n}\n.cug-badge {\n  display: inline-flex;\n  align-items: center;\n  gap: 9px;\n  margin-bottom: 28px;\n  padding: 7px 12px;\n  color: var(--green-dark);\n  background: rgba(255,255,255,.68);\n  border: 1px solid rgba(8,116,100,.18);\n  border-radius: 999px;\n  font-size: 12px;\n  font-weight: 800;\n  letter-spacing: .08em;\n  text-transform: uppercase;\n}\n.cug-badge::before {\n  content: \"\";\n  width: 8px;\n  height: 8px;\n  background: var(--green);\n  border-radius: 50%;\n  box-shadow: 0 0 0 4px rgba(8,116,100,.12);\n}\n.cug-hero-lead {\n  max-width: 790px;\n  margin: 30px 0 0;\n  font-size: clamp(1.12rem, 2vw, 1.38rem);\n  line-height: 1.55;\n}\n.cug-proof {\n  display: grid;\n  grid-template-columns: repeat(4, 1fr);\n  gap: 22px;\n  margin-top: 58px;\n  padding-top: 28px;\n  border-top: 1px solid rgba(19,44,43,.14);\n}\n.cug-proof-item {\n  color: var(--ink-soft);\n  font-size: 14px;\n  line-height: 1.45;\n}\n.cug-proof-item strong {\n  display: block;\n  margin-bottom: 4px;\n  color: var(--ink);\n  font-size: 15px;\n}\n.cug-two-col {\n  display: grid;\n  grid-template-columns: 1.15fr .85fr;\n  gap: clamp(45px, 8vw, 100px);\n  align-items: start;\n}\n.cug-definition {\n  margin: 0;\n  font-size: 1.1rem;\n}\n.cug-definition + .cug-definition { margin-top: 18px; }\n.cug-panel {\n  padding: clamp(28px, 4vw, 44px);\n  background: var(--mint-soft);\n  border: 1px solid var(--line);\n  border-radius: 18px;\n}\n.cug-panel-title {\n  margin-bottom: 20px !important;\n  font-size: 1.35rem !important;\n}\n.cug-question {\n  display: grid;\n  grid-template-columns: 30px 1fr;\n  gap: 12px;\n  align-items: start;\n  padding: 15px 0;\n  border-bottom: 1px solid var(--line);\n  color: var(--ink);\n  font-weight: 680;\n}\n.cug-question:last-child { border-bottom: 0; }\n.cug-number {\n  color: var(--green);\n  font-size: 12px;\n  font-weight: 850;\n  letter-spacing: .06em;\n}\n.cug-cream { background: var(--cream); }\n.cug-grid {\n  display: grid;\n  grid-template-columns: repeat(4, minmax(0, 1fr));\n  gap: 18px;\n}\n.cug-card {\n  min-height: 215px;\n  padding: 29px;\n  background: var(--white);\n  border: 1px solid #dedfd7;\n  border-radius: 15px;\n  box-shadow: 0 12px 32px rgba(19,44,43,.045);\n}\n.cug-card-mark {\n  display: inline-block;\n  width: 34px;\n  height: 4px;\n  margin-bottom: 24px;\n  background: var(--green);\n  border-radius: 99px;\n}\n.cug-card p {\n  margin: 0;\n  font-size: 15px;\n  line-height: 1.55;\n}\n.cug-compounds {\n  display: grid;\n  grid-template-columns: repeat(4, minmax(0, 1fr));\n  gap: 12px;\n}\n.cug-compound {\n  padding: 19px 20px;\n  background: var(--mint-soft);\n  border: 1px solid var(--line);\n  border-radius: 10px;\n}\n.cug-compound strong {\n  display: block;\n  color: var(--ink);\n  font-size: 16px;\n}\n.cug-compound span {\n  display: block;\n  margin-top: 3px;\n  color: var(--ink-soft);\n  font-size: 12px;\n  line-height: 1.35;\n}\n.cug-dark {\n  color: var(--white);\n  background:\n    radial-gradient(circle at 85% 30%, rgba(87,207,177,.11), transparent 28%),\n    var(--ink);\n}\n.cug-dark h2,\n.cug-dark h3 { color: var(--white); }\n.cug-dark p { color: #c5d6d2; }\n.cug-dark .cug-eyebrow { color: #78d2bd !important; }\n.cug-evidence-layout {\n  display: grid;\n  grid-template-columns: .78fr 1.22fr;\n  gap: clamp(45px, 8vw, 100px);\n  align-items: start;\n}\n.cug-evidence-list {\n  display: grid;\n  gap: 12px;\n}\n.cug-evidence {\n  display: grid;\n  grid-template-columns: 115px 1fr;\n  gap: 20px;\n  padding: 23px 25px;\n  background: rgba(255,255,255,.055);\n  border: 1px solid rgba(255,255,255,.1);\n  border-radius: 12px;\n}\n.cug-tier {\n  color: #78d2bd;\n  font-size: 12px;\n  font-weight: 850;\n  letter-spacing: .08em;\n  text-transform: uppercase;\n}\n.cug-evidence p { margin: 0; font-size: 15px; }\n.cug-framework {\n  display: grid;\n  grid-template-columns: repeat(3, 1fr);\n  gap: 18px;\n}\n.cug-framework-card {\n  padding: 31px;\n  background: var(--mint-soft);\n  border-radius: 15px;\n}\n.cug-framework-card small {\n  display: block;\n  margin-bottom: 18px;\n  color: var(--green);\n  font-weight: 850;\n  letter-spacing: .1em;\n}\n.cug-framework-card p { margin-bottom: 0; font-size: 15px; }\n.cug-method-grid {\n  display: grid;\n  grid-template-columns: repeat(4, minmax(0, 1fr));\n  gap: 1px;\n  overflow: hidden;\n  background: var(--line);\n  border: 1px solid var(--line);\n  border-radius: 16px;\n}\n.cug-method {\n  padding: 31px 27px;\n  background: var(--white);\n}\n.cug-method-index {\n  display: block;\n  margin-bottom: 38px;\n  color: var(--green);\n  font-size: 12px;\n  font-weight: 850;\n  letter-spacing: .1em;\n}\n.cug-method p { margin-bottom: 0; font-size: 15px; }\n.cug-final {\n  padding: 60px 0;\n  background: var(--cream);\n}\n.cug-disclaimer {\n  max-width: 980px;\n  margin: 0 auto;\n  padding: 24px 27px;\n  background: rgba(255,255,255,.7);\n  border-left: 4px solid var(--green);\n  border-radius: 0 10px 10px 0;\n}\n.cug-disclaimer p {\n  margin: 0;\n  color: var(--ink-soft);\n  font-size: 13px;\n  line-height: 1.6;\n}\n@media (max-width: 980px) {\n  .cug-proof,\n  .cug-grid,\n  .cug-compounds,\n  .cug-method-grid { grid-template-columns: repeat(2, 1fr); }\n  .cug-two-col,\n  .cug-evidence-layout { grid-template-columns: 1fr; }\n}\n@media (max-width: 700px) {\n  .cug-home { font-size: 17px; }\n  .cug-proof,\n  .cug-grid,\n  .cug-compounds,\n  .cug-framework,\n  .cug-method-grid { grid-template-columns: 1fr; }\n  .cug-evidence { grid-template-columns: 1fr; gap: 8px; }\n  .cug-card { min-height: 0; }\n}\n<\/style>\n<p><main class=\"cug-home\"><\/p>\n<header class=\"cug-hero\">\n<div class=\"cug-shell\">\n<div class=\"cug-badge\">Independent peptide research<\/div>\n<h1>The peptide research universe, mapped.<\/h1>\n<p class=\"cug-hero-lead\">Compound Universe Genome translates complex peptide science into clear, evidence-tiered research profiles\u2014separating human outcomes, animal findings, laboratory mechanisms, safety signals, and regulatory facts.<\/p>\n<div class=\"cug-proof\" aria-label=\"Editorial standards\">\n<div class=\"cug-proof-item\"><strong>Primary literature<\/strong>Research traced to PubMed, original DOIs, trials, and regulators.<\/div>\n<div class=\"cug-proof-item\"><strong>Evidence classified<\/strong>Human, animal, in-vitro, and regulatory evidence kept distinct.<\/div>\n<div class=\"cug-proof-item\"><strong>Limits disclosed<\/strong>Uncertainty, weak study design, and missing safety data remain visible.<\/div>\n<div class=\"cug-proof-item\"><strong>No peptide sales<\/strong>An informational research project without a product storefront.<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/header>\n<section class=\"cug-section\">\n<div class=\"cug-shell cug-two-col\">\n<div>\n<p class=\"cug-eyebrow\">What CU-Genome is<\/p>\n<h2>A navigable genome of peptide evidence.<\/h2>\n<p class=\"cug-definition\"><strong>Compound Universe Genome<\/strong>, abbreviated as <strong>CU-Genome<\/strong>, is an independent informational research project covering peptides, peptide therapeutics, signaling compounds, and related investigational molecules.<\/p>\n<p class=\"cug-definition\">The project maps the complete evidence chain behind each compound: molecular target, proposed mechanism of action, study model, human clinical outcomes, adverse events, approval status, and the questions science has not yet answered.<\/p>\n<p class=\"cug-definition\">CU-Genome does not treat biological plausibility as clinical proof. A laboratory mechanism, an animal experiment, a controlled human trial, and a regulatory decision represent different kinds of evidence\u2014and they are presented that way.<\/p>\n<\/p><\/div>\n<aside class=\"cug-panel\">\n<h3 class=\"cug-panel-title\">Every research profile answers five questions<\/h3>\n<div class=\"cug-question\"><span class=\"cug-number\">01<\/span><span>What is the peptide or compound?<\/span><\/div>\n<div class=\"cug-question\"><span class=\"cug-number\">02<\/span><span>How is it proposed to work?<\/span><\/div>\n<div class=\"cug-question\"><span class=\"cug-number\">03<\/span><span>What has actually been studied?<\/span><\/div>\n<div class=\"cug-question\"><span class=\"cug-number\">04<\/span><span>What are the known risks and unknowns?<\/span><\/div>\n<div class=\"cug-question\"><span class=\"cug-number\">05<\/span><span>What is its current regulatory status?<\/span><\/div>\n<\/aside><\/div>\n<\/section>\n<section class=\"cug-section cug-cream\">\n<div class=\"cug-shell\">\n<p class=\"cug-eyebrow\">The research landscape<\/p>\n<h2>Peptide science across biological systems<\/h2>\n<p class=\"cug-intro\">CU-Genome organizes peptide research by biological system and study objective. These topic areas connect mechanisms, individual compounds, experimental models, clinical findings, safety data, and regulatory context.<\/p>\n<div class=\"cug-grid\">\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Healing and recovery<\/h3>\n<p>BPC-157, thymosin beta-4\u2013related research, tissue repair, tendon models, wound healing, angiogenesis, and gastrointestinal studies.<\/p>\n<\/article>\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Weight and metabolism<\/h3>\n<p>GLP-1, GIP, and glucagon receptor agonism, obesity trials, glycemic control, appetite signaling, and body-composition outcomes.<\/p>\n<\/article>\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Skin and hair<\/h3>\n<p>GHK-Cu, copper peptides, collagen, extracellular-matrix biology, skin remodeling, wound response, and hair research.<\/p>\n<\/article>\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Muscle and performance<\/h3>\n<p>Growth-hormone secretagogues, GHRH analogs, lean mass, exercise physiology, recovery, and performance-related evidence.<\/p>\n<\/article>\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Brain, sleep, and cognition<\/h3>\n<p>Peptide research involving neurological pathways, cognition, mood, circadian biology, neuroprotection, and sleep.<\/p>\n<\/article>\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Immune and inflammation<\/h3>\n<p>Thymic peptides, immune signaling, inflammatory pathways, host defense, cellular repair, and preclinical models.<\/p>\n<\/article>\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Sexual health<\/h3>\n<p>Melanocortin signaling and peptide studies related to sexual desire, arousal, reproductive biology, and function.<\/p>\n<\/article>\n<article class=\"cug-card\">\n          <span class=\"cug-card-mark\"><\/span><\/p>\n<h3>Aging and longevity<\/h3>\n<p>Experimental compounds, cellular senescence, mitochondrial biology, aging pathways, lifespan models, and translational limits.<\/p>\n<\/article><\/div>\n<\/p><\/div>\n<\/section>\n<section class=\"cug-section\">\n<div class=\"cug-shell\">\n<p class=\"cug-eyebrow\">Compound knowledge base<\/p>\n<h2>Widely researched and discussed peptides<\/h2>\n<p class=\"cug-intro\">The peptide landscape includes approved medicines, discontinued drugs, clinical-stage candidates, naturally occurring peptides, synthetic analogs, and research-only compounds. Their evidence and legal status are not interchangeable.<\/p>\n<div class=\"cug-compounds\">\n<div class=\"cug-compound\"><strong>BPC-157<\/strong><span>Primarily preclinical repair research<\/span><\/div>\n<div class=\"cug-compound\"><strong>GHK-Cu<\/strong><span>Copper peptide and matrix biology<\/span><\/div>\n<div class=\"cug-compound\"><strong>TB-500<\/strong><span>Thymosin beta-4\u2013related fragment<\/span><\/div>\n<div class=\"cug-compound\"><strong>Tesamorelin<\/strong><span>GHRH analog with human clinical evidence<\/span><\/div>\n<div class=\"cug-compound\"><strong>Sermorelin<\/strong><span>Growth hormone\u2013releasing analog<\/span><\/div>\n<div class=\"cug-compound\"><strong>Ipamorelin<\/strong><span>Growth hormone secretagogue research<\/span><\/div>\n<div class=\"cug-compound\"><strong>Retatrutide<\/strong><span>Investigational triple receptor agonist<\/span><\/div>\n<div class=\"cug-compound\"><strong>Semaglutide<\/strong><span>GLP-1 receptor agonist<\/span><\/div>\n<div class=\"cug-compound\"><strong>Tirzepatide<\/strong><span>Dual GIP and GLP-1 receptor agonist<\/span><\/div>\n<div class=\"cug-compound\"><strong>PT-141<\/strong><span>Melanocortin receptor agonist<\/span><\/div>\n<div class=\"cug-compound\"><strong>Thymosin alpha-1<\/strong><span>Immune-modulating peptide research<\/span><\/div>\n<div class=\"cug-compound\"><strong>CJC-1295<\/strong><span>Long-acting GHRH analog research<\/span><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<section class=\"cug-section cug-dark\">\n<div class=\"cug-shell cug-evidence-layout\">\n<div>\n<p class=\"cug-eyebrow\">Evidence is not one thing<\/p>\n<h2>Different studies answer different questions.<\/h2>\n<p>CU-Genome classifies claims according to the type and maturity of the underlying evidence. This prevents an effect observed in isolated cells or rodents from being presented as an established human outcome.<\/p>\n<\/p><\/div>\n<div class=\"cug-evidence-list\">\n<div class=\"cug-evidence\">\n          <span class=\"cug-tier\">In vitro<\/span><\/p>\n<p>Experiments in cells, tissues, or isolated biological systems that can explore mechanisms but cannot establish a clinical effect.<\/p>\n<\/p><\/div>\n<div class=\"cug-evidence\">\n          <span class=\"cug-tier\">Animal<\/span><\/p>\n<p>Preclinical models that may identify biological signals, safety concerns, or therapeutic hypotheses requiring human validation.<\/p>\n<\/p><\/div>\n<div class=\"cug-evidence\">\n          <span class=\"cug-tier\">Human<\/span><\/p>\n<p>Observational studies, pharmacology research, and controlled clinical trials, evaluated according to design and outcome quality.<\/p>\n<\/p><\/div>\n<div class=\"cug-evidence\">\n          <span class=\"cug-tier\">Regulatory<\/span><\/p>\n<p>Approval labels, safety communications, compounding decisions, and other legal documents dated to their jurisdiction.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<section class=\"cug-section\">\n<div class=\"cug-shell\">\n<p class=\"cug-eyebrow\">Research beyond efficacy<\/p>\n<h2>Mechanisms, comparisons, safety, and status<\/h2>\n<p class=\"cug-intro\">Useful peptide research requires more than listing potential benefits. CU-Genome places biological findings inside a broader framework that includes evidence quality, pharmacology, safety, legality, and clinical relevance.<\/p>\n<div class=\"cug-framework\">\n<article class=\"cug-framework-card\">\n          <small>01 \/ MECHANISMS<\/small><\/p>\n<h3>How peptides interact with biology<\/h3>\n<p>Receptor activity, signaling pathways, half-life, bioavailability, metabolism, and the difference between a plausible mechanism and a demonstrated outcome.<\/p>\n<\/article>\n<article class=\"cug-framework-card\">\n          <small>02 \/ COMPARISONS<\/small><\/p>\n<h3>Like-for-like evidence<\/h3>\n<p>Compounds are compared by molecular target, study population, evidence maturity, measured outcomes, safety information, and regulatory position.<\/p>\n<\/article>\n<article class=\"cug-framework-card\">\n          <small>03 \/ REGULATION<\/small><\/p>\n<h3>Status with a date and jurisdiction<\/h3>\n<p>FDA approval, compounding eligibility, prescribing rules, research status, and sporting restrictions are separate questions and can change over time.<\/p>\n<\/article><\/div>\n<\/p><\/div>\n<\/section>\n<section class=\"cug-section cug-cream\">\n<div class=\"cug-shell\">\n<p class=\"cug-eyebrow\">The CU-Genome editorial standard<\/p>\n<h2>Evidence before excitement.<\/h2>\n<p class=\"cug-intro\">Every research summary is designed to show not only what a study reports, but also how much confidence that study deserves and what it cannot establish.<\/p>\n<div class=\"cug-method-grid\">\n<article class=\"cug-method\">\n          <span class=\"cug-method-index\">01 \/ SOURCE<\/span><\/p>\n<h3>Start with primary literature<\/h3>\n<p>Original research, trial registries, PubMed records, DOIs, approved labels, and regulator documents take priority over commercial summaries.<\/p>\n<\/article>\n<article class=\"cug-method\">\n          <span class=\"cug-method-index\">02 \/ CLASSIFY<\/span><\/p>\n<h3>Label the evidence<\/h3>\n<p>Laboratory, animal, observational, controlled human, systematic-review, and regulatory evidence are identified separately.<\/p>\n<\/article>\n<article class=\"cug-method\">\n          <span class=\"cug-method-index\">03 \/ QUALIFY<\/span><\/p>\n<h3>Report the limitations<\/h3>\n<p>Small samples, weak controls, surrogate outcomes, conflicts, absent replication, and missing long-term safety data remain visible.<\/p>\n<\/article>\n<article class=\"cug-method\">\n          <span class=\"cug-method-index\">04 \/ MAINTAIN<\/span><\/p>\n<h3>Date material updates<\/h3>\n<p>New trials, approvals, safety communications, and regulatory decisions are incorporated with a visible review date.<\/p>\n<\/article><\/div>\n<\/p><\/div>\n<\/section>\n<footer class=\"cug-final\">\n<div class=\"cug-shell\">\n<div class=\"cug-disclaimer\">\n<p><strong>Medical and regulatory disclaimer:<\/strong> Compound Universe Genome is an independent educational resource, not a medical provider, pharmacy, laboratory, or peptide seller. Content is informational only and is not medical advice, diagnosis, treatment, or a recommendation to obtain or use any substance. Many compounds discussed are investigational or are not approved for human use. Legal and regulatory status varies by jurisdiction and changes over time. Consult a qualified, licensed clinician for medical decisions.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/footer>\n<p><\/main><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Independent peptide research The peptide research universe, mapped. Compound Universe Genome translates complex peptide science into clear, evidence-tiered research profiles\u2014separating human outcomes, animal findings, laboratory mechanisms, safety signals, and regulatory facts. Primary literatureResearch traced to PubMed, original DOIs, trials, and regulators. Evidence classifiedHuman, animal, in-vitro, and regulatory evidence kept distinct. Limits disclosedUncertainty, weak study design, &#8230; <a title=\"Compound Universe Genome\" class=\"read-more\" href=\"https:\/\/cu-genome.org\/\" aria-label=\"Read more about Compound Universe Genome\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-10","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/cu-genome.org\/index.php?rest_route=\/wp\/v2\/pages\/10","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cu-genome.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cu-genome.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cu-genome.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cu-genome.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10"}],"version-history":[{"count":2,"href":"https:\/\/cu-genome.org\/index.php?rest_route=\/wp\/v2\/pages\/10\/revisions"}],"predecessor-version":[{"id":13,"href":"https:\/\/cu-genome.org\/index.php?rest_route=\/wp\/v2\/pages\/10\/revisions\/13"}],"wp:attachment":[{"href":"https:\/\/cu-genome.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}